Medtech M&A: Mid-Tiers Poised To Strike In 2015
This may be the year that mid-sized medtech companies step up their acquisition pace to better compete against larger rivals. To be sure, these players won’t rival Medtronic, Covidien, or the other pre-megamerger partners in size or scope, but they could be in a great position to scoop up smaller companies and technologies in a bid to widen or extend their own pipelines.
You may also be interested in...
Medtech manufacturers saw 2014 as the year of the medtech mega-merger and a rebound in IPOs. But the market is changing, and companies are increasingly cast as service providers who must deliver value.
Orthopedic companies now target the so-called extremities as an area of capable of producing double-digit growth in sales. To be sure, the markets are considerably smaller than hips or knees, but multinational leaders can’t ignore untapped potential when their core markets are stagnant, and a new front is forming in the battle for foot and ankle supremacy around an old but still underutilized device – total ankle replacement implants.
Amunix’s XTEN technology for half-life extension and precise drug delivery has been used by multiple partners over the past 15 years, but now the firm is building its own cancer therapy pipeline.